enVVeno Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

enVVeno Medical hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.7%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$1.55
Prognose der Dividendenrendite	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von NVNO in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von NVNO gestiegen sind.

Dividendenrendite im Vergleich zum Markt

enVVeno Medical Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von NVNO im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (NVNO)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Medical Equipment)	1.7%
Analystenprognose (NVNO) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von NVNO im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von NVNO im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von NVNO, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da NVNO keine Ausschüttungen gemeldet hat.

enVVeno Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

enVVeno Medical Corporation has completed a Follow-on Equity Offering in the amount of $15.000003 million.

No longer forecast to breakeven

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

enVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial

enVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting

enVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve

New minor risk - Share price stability

Forecast to breakeven in 2026

enVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

New minor risk - Shareholder dilution

Price target decreased by 15% to US$20.40

enVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

New major risk - Share price stability

Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study

New minor risk - Share price stability

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria

Insufficient new directors

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Insufficient new directors

enVVeno Medical: Unique Exposure To Venous Treatment Domain

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

Price target decreased to US$24.00

No longer forecast to breakeven

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Venovalve, Potential Treatment for Deep Venous Chronic Venous Insufficiency

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Price target decreased to US$26.00

Forecast to breakeven in 2024

New 90-day low: US$7.37

Price target lowered to US$28.00

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $35.999992 million.

Hancock Jaffe Laboratories, Inc. Appoints Craig Glynn Chief Financial Officer

Hancock Jaffe Laboratories finance chief sheds interim tag

Hancock Jaffe Receives Formal Notification from the Nasdaq Hearings Panel

Hancock Jaffe approves 1:25 reverse stock split

Hancock Jaffe Laboratories, Inc. announced delayed 10-Q filing

Hancock Jaffe Laboratories, Inc., Annual General Meeting, Dec 17, 2020

Hancock Jaffe Laboratories, Inc. (NasdaqCM:HJLI) entered into non-binding letter of intent to acquire Catheter Precision, Inc.

New 90-day high - US$0.56

New 90-day low - US$0.31

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

New 90-day low - US$0.31

Hancock Jaffe Laboratories, Inc. announced that it has received $1.556 million in funding

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $4 million.

Hancock Jaffe Laboratories, Inc. announced that it expects to receive $1.556 million in funding

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen